Langerhans cell histiocytosis
Conditions
Interventions
None listed
Sponsors
Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed as LCH, the diagnostic criteria are lesion biopsy pathological examination and immunohistochemical staining CD1a positive and/or CD207 (ie Langerin) positive; 2. Under the age of 18 at the time of diagnosis; 3. Have not received any anti-tumor treatment before diagnosis; 4. BRAF-V600E/MAP2K1/BRAF other/ARAF/MAP3K10 and other pathogenicity-related MAPK and other signaling pathway gene mutations in lesion tissue or peripheral blood are positive at the time of diagnosis; 5. Obtain the consent of the guardian of the child and the child himself (over 8 years old), and sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Screening for relevant gene mutations was not carried out at the time of diagnosis; 2. No peripheral blood gene mutation detection at any time point during diagnosis and treatment; 3. Those who cannot carry out standardized diagnosis and treatment according to the treatment plan of our hospital; 4. Patients who cannot comply during the trial and/or follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression/relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| Death; | — |
Countries
China
Contacts
Public ContactCui Lei
Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University
Outcome results
None listed